Introduction
Breast cancer remains one of the most prevalent malignancies affecting women globally and is a leading cause of cancer-related mortality in females. Despite advances in chemotherapy, radiotherapy, and hormonal therapies, the adverse side effects and resistance associated with conventional treatments have spurred interest in alternative and complementary therapies, particularly those derived from natural products [1].
One such compound of interest is turmeric, derived from the rhizome of Curcuma longa. It has been traditionally used in Ayurveda and Chinese medicine for its anti-inflammatory, antioxidant, and anticancer properties.
The bioactive constituent of turmeric, curcumin, has been extensively studied for its multifaceted roles in inhibiting cancer progression, including the induction of apoptosis, inhibition of angiogenesis, and suppression of metastasis [2, 3].
Preclinical studies have demonstrated that curcumin modulates multiple molecular targets involved in cancer signaling pathways. These include the downregulation of nuclear factor kappa B (NF-κB), cyclooxygenase-2 (COX- 2), and Bcl-2, along with the activation of pro-apoptotic proteins such as p53, Bax, and caspase-3 [4]. In vivo models involving rodents have validated the chemopreventive effects of curcumin, showing a significant reduction in tumor burden and enhanced survival rates when administered orally or intraperitoneally [5].
Moreover, oxidative stress and chronic inflammation are known contributors to tumor initiation and progression. Curcumin’s ability to act as a potent scavenger of reactive oxygen species (ROS), along with its inhibitory effect on pro-inflammatory cytokines like TNF-α and IL-6, positions it as a valuable agent in cancer therapy [6]. Given its low toxicity and high safety margin in animal models, turmeric extract has emerged as a promising candidate for further research in breast cancer treatment, particularly in hormone-dependent and chemically induced tumor models in rats [7, 8].
This study investigates the therapeutic potential of Curcuma longa in female rats with experimentally induced breast cancer, aiming to elucidate the underlying molecular mechanisms and evaluate key biomarkers associated with tumor suppression.
Discussion
This study investigated the therapeutic potential of Curcuma longa (turmeric) in the treatment of chemically induced breast cancer in female rats, with a focus on tumor growth suppression, modulation of apoptotic and inflammatory pathways, and changes in molecular markers. The findings reinforce the anticancer efficacy of turmeric, primarily attributed to its bioactive polyphenol curcumin, and are consistent with previously published in vitro and in vivo studies [10].
Rats treated with turmeric extract demonstrated significantly reduced tumor volumes, with the highest inhibition seen in the 400 mg/kg dose group. This aligns with prior reports where curcumin inhibited tumor growth in DMBA-induced mammary carcinogenesis via cell cycle arrest and apoptosis [11-15]. The reduction in tumor burden can be attributed to the antiproliferative effect of curcumin, which has been shown to interfere with mitogenic signaling and suppress angiogenesis through VEGF downregulation [16-20].
Caspase-3, a key executioner of apoptosis, was significantly upregulated in turmeric-treated rats in a dose-dependent manner, indicating enhanced programmed cell death. Curcumin is known to activate mitochondrial apoptotic pathways by increasing Bax/Bcl-2 ratio and stimulating caspase cascade activation, ultimately leading to DNA fragmentation and cell death in cancer cells [21, 22].
The upregulation of p53, a tumor suppressor protein, further corroborates this finding. p53-mediated apoptosis plays a central role in eliminating cells with DNA damage and abnormal proliferation. Curcumin has been previously documented to stabilize and activate p53 through suppression of MDM2 and enhancement of DNA damage response signaling [23].
Chronic inflammation is a hallmark of carcinogenesis. In this study, turmeric significantly reduced TNF-α and IL-6 levels, reflecting its potent anti-inflammatory properties. Curcumin modulates inflammatory responses by inhibiting nuclear factor-kappa B (NF-κB) activation and its downstream pro-inflammatory gene products, including cytokines, chemokines, and COX-2 [24].
The inverse relationship between TNF-α levels and tumor reduction further supports the role of inflammatory cytokines in promoting tumor growth, angiogenesis, and metastasis. This mechanism highlights curcumin’s ability to interrupt the tumor-promoting microenvironment, an essential aspect of its chemopreventive efficacy.
Tumor tissues often exhibit elevated oxidative stress, contributing to genetic instability and tumor progression. The significant reduction in MDA levels and enhancement of antioxidant enzymes (SOD, catalase) in turmeric-treated groups indicates effective oxidative stress mitigation. Curcumin is well-documented as a scavenger of reactive oxygen species (ROS), and this antioxidant capacity further contributes to its protective role against carcinogenesis [25, 26].
This study demonstrated a clear dose-response relationship, with the highest curative effects seen in the 400 mg/kg group. These doses were well-tolerated with no adverse behavioral or physiological effects observed, consistent with earlier toxicity studies that reported low systemic toxicity of curcumin even at high doses [27-31]. In conclusion, the present study demonstrates that Curcuma longa (turmeric) possesses potent therapeutic potential in the management of breast cancer in female rats. Oral administration of turmeric extract led to a significant and dose-dependent reduction in tumor volume, along with favorable modulation of molecular markers related to apoptosis (Caspase-3, p53), inflammation (TNF-α, NF-κB), and oxidative stress (MDA, SOD).
The observed effects are attributed primarily to curcumin, the principal bioactive component of turmeric, which exerted multifaceted anticancer effects by promoting programmed cell death, inhibiting pro-inflammatory pathways, and restoring redox balance. Notably, the highest dose (400 mg/kg) yielded the most pronounced therapeutic benefit, with no signs of systemic toxicity or adverse effects.
These findings suggest that turmeric, a widely available and well-tolerated natural compound, could serve as a promising complementary agent in breast cancer therapy, particularly for early-stage or hormone- responsive tumors. However, further investigations including mechanistic molecular studies, pharmacokinetic profiling, and clinical trials are warranted to validate these results and translate them into therapeutic applications for humans.
Acknowledgements
The authors would like to express their sincere gratitude to the Scientific Research Center, Al-Ayen Iraqi University, for providing the necessary facilities and support to carry out this research. Special thanks are extended to the technical staff and animal care personnel for their assistance in animal handling, histopathological preparations, and data collection.
We also acknowledge the contribution of [Insert Collaborator Name, if any], whose guidance and critical feedback significantly enriched the scientific rigor of this work.
This study was conducted as part of a non-commercial academic investigation. No external funding was received.
Conflict of Interest
The authors declare no conflict of interest related to the publication of this research. The study was conducted independently and received no financial support or sponsorship from commercial or institutional entities that could influence the results or interpretation of the data.